Developer docs
API playgroundTry for free, no card

Search company profiles

UNITY Biotechnology

Full company profile

uuid0002gg5

Namestring
UNITY Biotechnology
Legal namestring
Unity Biotechnology
Company typeenum
Public
Founded yearint
2009
Descriptiontext

UNITY Biotechnology was a clinical-stage biotechnology company founded in 2009 and formerly based in South San Francisco, California, that developed senolytic therapeutics — small-molecule drugs designed to selectively eliminate senescent cells which accumulate with age and drive tissue dysfunction. The company's therapeutic pipeline targeted age-related diseases including osteoarthritis and diabetic macular edema (DME). Its lead osteoarthritis senolytic candidate failed to meet primary endpoints in a 2020 Phase 2 trial, while its DME senolytic candidate produced positive Phase 2 results that did not ultimately translate into a viable path to approval or commercialization. UNITY operated with a headcount of 11–50 employees and was funded through a combination of venture rounds (notably a $116M round in 2016 led by Bezos Expeditions and a $55M financing in 2018) and its 2018 initial public offering on NASDAQ under the ticker UBX.

The company's business model was that of a traditional pre-revenue biotech: it generated no product revenue, sustained significant operating losses (~$93.8M net loss in 2020, narrowing to ~$26.0M by 2024 as R&D wound down), and financed operations through equity capital. Its target customer base — had products reached market — would have been patients suffering from age-related degenerative conditions, accessed through ophthalmologists and other specialty physicians. Following clinical trial failures and capital depletion, UNITY raised approximately $4.38M in a final warrant exercise in November 2023 and ultimately ceased operations in September 2025, with the corporate website confirming the company is no longer operating and correspondence redirected to a Foxboro, MA address and a third-party email.

Short descriptiontext

UNITY Biotechnology was a clinical-stage biotech (NASDAQ: UBX) that developed senolytic small-molecule drugs to eliminate senescent cells and treat age-related diseases such as osteoarthritis and diabetic macular edema before ceasing operations in September 2025.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
senolytic drug development, age-related disease therapeutics, cellular senescence therapy, anti-aging biotechnology, clinical stage pharmaceuticals
Industry1 code
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Senolytic Therapeutics for Age-Related Diseases
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

UNITY Biotechnology developed senolytic therapeutics designed to selectively target and eliminate senescent cells that accumulate with age and contribute to tissue dysfunction. The company's drug candidate portfolio targeted age-related diseases including diabetic macular edema and osteoarthritis. UNITY was a clinical-stage biopharmaceutical company that ceased operations in September 2025 following clinical trial setbacks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 2 trial showed positive results for diabetic macular edema treatment
+1 more record
Product overview1 text field

UNITY Biotechnology was a biotechnology company developing senolytic drug therapies targeting cellular senescence to treat age-related diseases. The company operated a portfolio of therapeutic candidates including treatments for diabetic macular edema (which achieved positive Phase 2 results) and osteoarthritis (which failed its 2020 trial). The company went public in 2018 and ceased operations in September 2025 following clinical trial setbacks and capital depletion.

Product and service3 records
1Senolytic Drug Development Program
CategorySenolytic drug development platform
Description

A clinical-stage drug development platform that produced proprietary senolytic therapeutics designed to selectively eliminate senescent cells which accumulate with age and contribute to tissue dysfunction. Targeted age-related diseases including osteoarthritis and diabetic macular edema.

2Diabetic Macular Edema Treatment
CategoryTherapeutic candidate (ophthalmology)
Description

An experimental senolytic treatment for diabetic macular edema that demonstrated positive Phase 2 trial results before UNITY ceased operations. Designed for patients with diabetic eye disease driven by senescent cell accumulation.

3Osteoarthritis Treatment
CategoryTherapeutic candidate (orthopedics)
Description

A senolytic drug candidate for osteoarthritis that failed to meet primary endpoints in a 2020 clinical trial, representing the pivotal setback that undermined UNITY's clinical pipeline and ultimately contributed to the company's shutdown.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing therapeutics that target the molecular drivers of aging. Comparable as a focused aging-therapeutics developer with a pipeline spanning age-related conditions.

TypeDirect peer
Description

Clinical-stage AI-driven biotech developing therapeutics targeting aging and age-related diseases, including senolytic and anti-fibrotic programs. Most directly comparable as a peer developing drugs against senescence biology.

TypeEmerging player
Description

Gene therapy company developing treatments for age-related diseases in humans and animals. Comparable as a small-cap aging-therapeutics developer with adjacent modality (gene therapy vs. small-molecule senolytics).

TypeBroad incumbent
Description

Major biopharmaceutical company with approved therapies (aflibercept/EYLEA) for diabetic macular edema. Comparable as a broad incumbent addressing the same ophthalmology indication UNITY's DME program targeted.

5Turn Biotechnologies
TypeEmerging player
Description

Clinical-stage company developing mRNA-based cellular reprogramming therapies for age-related conditions. Comparable as an emerging player tackling cellular aging, though using a different delivery modality than UNITY's senolytics.

6AgeX Therapeutics
TypeDirect peer
Description

Biotechnology company focused on developing therapeutics targeting biological aging and age-related degenerative diseases. Comparable as a direct aging-therapeutics peer, though AgeX itself has also faced significant clinical and capital headwinds.

TypeBroad incumbent
Description

Global pharmaceutical company with significant ophthalmology franchise (Lucentis, Beovu) treating DME. Comparable as a broad incumbent in the DME therapeutic area UNITY was pursuing.

TypeBroad incumbent
Description

Alphabet-backed R&D organization focused on aging biology and age-related disease therapeutics. Comparable as a well-capitalized aging-therapeutics research entity targeting fundamental mechanisms of senescence, though operating at vastly greater scale than UNITY.

TypeDirect peer
Description

Biotech developing therapeutics based on cellular reprogramming and longevity science to treat age-related diseases. Comparable as a peer pursuing first-in-class interventions against fundamental aging mechanisms.

TypeEmerging player
Description

Early-stage biotech developing recombinant protein therapeutics that target aging pathways, including GDF11. Comparable as a younger aging-therapeutics developer with partial mechanism overlap with senolytic strategies.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UNITY Biotechnology

Senolytic Therapeutics for Age-Related Diseasesunitybiotechnology.com

UNITY Biotechnology was a clinical-stage biotech (NASDAQ: UBX) that developed senolytic small-molecule drugs to eliminate senescent cells and treat age-related diseases such as osteoarthritis and diabetic macular edema before ceasing operations in September 2025.

What UNITY Biotechnology does

UNITY Biotechnology was a clinical-stage biotechnology company founded in 2009 and formerly based in South San Francisco, California, that developed senolytic therapeutics — small-molecule drugs designed to selectively eliminate senescent cells which accumulate with age and drive tissue dysfunction. The company's therapeutic pipeline targeted age-related diseases including osteoarthritis and diabetic macular edema (DME). Its lead osteoarthritis senolytic candidate failed to meet primary endpoints in a 2020 Phase 2 trial, while its DME senolytic candidate produced positive Phase 2 results that did not ultimately translate into a viable path to approval or commercialization. UNITY operated with a headcount of 11–50 employees and was funded through a combination of venture rounds (notably a $116M round in 2016 led by Bezos Expeditions and a $55M financing in 2018) and its 2018 initial public offering on NASDAQ under the ticker UBX.

The company's business model was that of a traditional pre-revenue biotech: it generated no product revenue, sustained significant operating losses (~$93.8M net loss in 2020, narrowing to ~$26.0M by 2024 as R&D wound down), and financed operations through equity capital. Its target customer base — had products reached market — would have been patients suffering from age-related degenerative conditions, accessed through ophthalmologists and other specialty physicians. Following clinical trial failures and capital depletion, UNITY raised approximately $4.38M in a final warrant exercise in November 2023 and ultimately ceased operations in September 2025, with the corporate website confirming the company is no longer operating and correspondence redirected to a Foxboro, MA address and a third-party email.

UNITY Biotechnology firmographics

Firmographics
Name
UNITY Biotechnology
Legal name
Unity Biotechnology
Website
https://unitybiotechnology.com
Company type
Public
Founded year
2009
Operating status
Closed
Headcount range
11–50 employees
Short description
UNITY Biotechnology was a clinical-stage biotech (NASDAQ: UBX) that developed senolytic small-molecule drugs to eliminate senescent cells and treat age-related diseases such as osteoarthritis and diabetic macular edema before ceasing operations in September 2025.
Ownership category
akta.pro rank

UNITY Biotechnology industry classification

Industry
Product category
Senolytic Therapeutics for Age-Related Diseases
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Senolytic drug development
  • Age-related disease therapeutics
  • Cellular senescence therapy
  • Anti-aging biotechnology
  • Clinical stage pharmaceuticals

Where UNITY Biotechnology is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

UNITY Biotechnology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

UNITY Biotechnology product offering

Product offering

Core offering

UNITY Biotechnology developed senolytic therapeutics designed to selectively target and eliminate senescent cells that accumulate with age and contribute to tissue dysfunction. The company's drug candidate portfolio targeted age-related diseases including diabetic macular edema and osteoarthritis. UNITY was a clinical-stage biopharmaceutical company that ceased operations in September 2025 following clinical trial setbacks.

Product overview

UNITY Biotechnology was a biotechnology company developing senolytic drug therapies targeting cellular senescence to treat age-related diseases. The company operated a portfolio of therapeutic candidates including treatments for diabetic macular edema (which achieved positive Phase 2 results) and osteoarthritis (which failed its 2020 trial). The company went public in 2018 and ceased operations in September 2025 following clinical trial setbacks and capital depletion.

Differentiator

Problem solved

Functional benefit

Products and services

  • Senolytic Drug Development Program A clinical-stage drug development platform that produced proprietary senolytic therapeutics designed to selectively eliminate senescent cells which accumulate with age and contribute to tissue dysfunction. Targeted age-related diseases including osteoarthritis and diabetic macular edema.
  • Diabetic Macular Edema Treatment An experimental senolytic treatment for diabetic macular edema that demonstrated positive Phase 2 trial results before UNITY ceased operations. Designed for patients with diabetic eye disease driven by senescent cell accumulation.
  • Osteoarthritis Treatment A senolytic drug candidate for osteoarthritis that failed to meet primary endpoints in a 2020 clinical trial, representing the pivotal setback that undermined UNITY's clinical pipeline and ultimately contributed to the company's shutdown.

Quantifiable outcome

  • Phase 2 trial showed positive results for diabetic macular edema treatment
  • +1 more outcomes

Companies that use UNITY Biotechnology

Customer profile

Segments1 record

Ideal customer profiles2 records

UNITY Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

UNITY Biotechnology partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves8 records

Expansion highlights3 records

UNITY Biotechnology competitors and assessment

Company assessment

Direct peers

  • BioAge Labs: Clinical-stage biotechnology company developing therapeutics that target the molecular drivers of aging. Comparable as a focused aging-therapeutics developer with a pipeline spanning age-related conditions.
  • Insilico Medicine: Clinical-stage AI-driven biotech developing therapeutics targeting aging and age-related diseases, including senolytic and anti-fibrotic programs. Most directly comparable as a peer developing drugs against senescence biology.
  • AgeX Therapeutics: Biotechnology company focused on developing therapeutics targeting biological aging and age-related degenerative diseases. Comparable as a direct aging-therapeutics peer, though AgeX itself has also faced significant clinical and capital headwinds.
  • Life Biosciences: Biotech developing therapeutics based on cellular reprogramming and longevity science to treat age-related diseases. Comparable as a peer pursuing first-in-class interventions against fundamental aging mechanisms.

Emerging players

  • Rejuvenate Bio: Gene therapy company developing treatments for age-related diseases in humans and animals. Comparable as a small-cap aging-therapeutics developer with adjacent modality (gene therapy vs. small-molecule senolytics).
  • Turn Biotechnologies: Clinical-stage company developing mRNA-based cellular reprogramming therapies for age-related conditions. Comparable as an emerging player tackling cellular aging, though using a different delivery modality than UNITY's senolytics.
  • Elevian: Early-stage biotech developing recombinant protein therapeutics that target aging pathways, including GDF11. Comparable as a younger aging-therapeutics developer with partial mechanism overlap with senolytic strategies.

Broad incumbents

  • Regeneron Pharmaceuticals: Major biopharmaceutical company with approved therapies (aflibercept/EYLEA) for diabetic macular edema. Comparable as a broad incumbent addressing the same ophthalmology indication UNITY's DME program targeted.
  • Novartis: Global pharmaceutical company with significant ophthalmology franchise (Lucentis, Beovu) treating DME. Comparable as a broad incumbent in the DME therapeutic area UNITY was pursuing.
  • Calico Life Sciences: Alphabet-backed R&D organization focused on aging biology and age-related disease therapeutics. Comparable as a well-capitalized aging-therapeutics research entity targeting fundamental mechanisms of senescence, though operating at vastly greater scale than UNITY.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

UNITY Biotechnology social profiles

Digital presence

UNITY Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UNITY Biotechnology leadership team

Management profile

Number of profiles

UNITY Biotechnology funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UNITY Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UNITY Biotechnology

What does UNITY Biotechnology do?

UNITY Biotechnology developed senolytic therapeutics designed to selectively target and eliminate senescent cells that accumulate with age and contribute to tissue dysfunction. The company's drug candidate portfolio targeted age-related diseases including diabetic macular edema and osteoarthritis. UNITY was a clinical-stage biopharmaceutical company that ceased operations in September 2025 following clinical trial setbacks.

Is UNITY Biotechnology a public or private company?

UNITY Biotechnology is a public company. It is classified as public and is currently closed.

When was UNITY Biotechnology founded?

UNITY Biotechnology was founded in 2009. It employs 11 to 50 people.

Where is UNITY Biotechnology based?

UNITY Biotechnology is headquartered in South San Francisco, United States, in the North America region.

Who are UNITY Biotechnology's main competitors?

Direct peers on record are BioAge Labs, Insilico Medicine, AgeX Therapeutics and Life Biosciences. Emerging players are Rejuvenate Bio, Turn Biotechnologies and Elevian. Broad incumbents are Regeneron Pharmaceuticals, Novartis and Calico Life Sciences.

Does UNITY Biotechnology have an API?

No public API is recorded for UNITY Biotechnology.

What industry is UNITY Biotechnology in?

UNITY Biotechnology's product category is Senolytic Therapeutics for Age-Related Diseases. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournJocasta Signs UCSF Licensing Agreement to Advance α-klotho for Managing Cognitive ImpairmentJocasta Neuroscience, Inc. has entered into a licensing agreement with the University of California, San Francisco (UCSF) to develop therapeutics based on α-klotho aimed at enhancing cognitive function. The agreement expands upon a previous license Jocasta acquired from Unity Biotechnology and grants exclusive rights to α-klotho-related intellectual property held by UCSF, specifically for neurodegenerative diseases. Jocasta plans to initiate Phase 1 human trials of its lead candidate, JN-0413, at the start of 2027.PR NewswireJocasta Signs UCSF Licensing Agreement to Advance α-klotho for Managing Cognitive ImpairmentJocasta Neuroscience, Inc. has entered into a new licensing agreement with the University of California, San Francisco (UCSF) to develop α-klotho-based therapies for cognitive impairment and neurodegenerative diseases. This deal supersedes and expands Jocasta's previous license from Unity Biotechnology, resulting in the termination of all outstanding milestone payments and royalty obligations to Unity. The company expects its lead candidate, JN-0413, to begin Phase 1 human trials at the start of 2027.EIN PresswireLongevity Market to reach USD 66.40 Billion by 2035 at 7.52% CAGRThe global longevity market is projected to grow from USD 34.57 billion in 2026 to USD 66.40 billion by 2035, a 7.52% CAGR. Growth is driven by aging demographics, senolytic pipeline maturation, and AI-driven drug discovery. North America leads with a 38% share, while Asia-Pacific is the fastest-growing region.MIT Technology ReviewWhy “reprogramming” is the buzziest approach to reversing aging right nowLife Biosciences dosed its first volunteer with an experimental eye reprogramming treatment for glaucoma, aiming to regenerate healthy nerves. The approach, based on reprogramming cells to a younger state, has attracted billions in funding, with Sinclair planning to test an oral reprogramming drug in a XPrize competition.New York PostInside the alarming cyborg future 'transhumanists' Elon Musk, Peter Thiel and Sam Altman are preparing forMajor tech executives including Elon Musk, Peter Thiel, and Sam Altman are investing in transhumanist technologies aimed at merging human consciousness with machines or achieving digital immortality, with investments spanning companies like Neuralink, OpenAI's Merge Labs, Minicircle, and Unity Biotechnology. The article presents a critical analysis of this ideology, citing MIT physicist Max Tegmark and tech reporter Taylor Lorenz who argue that transhumanist beliefs are driving reckless AI innovation that prioritizes the vision of tech founders over human wellbeing. Critics warn that the general public finds this vision "horrifying" and question whether humanity would retain autonomy if it "merged" with more intelligent machines.ClarivatePharmas and biotechs are investing in new treatments for diseases of agingSince 2024, longevity-focused startups have attracted $8.5 billion in venture capital as major pharmaceutical companies including Eli Lilly, Novo Nordisk, and Novartis have built dedicated divisions around aging biology, driven by GLP-1 drugs demonstrating multi-system benefits across cardiovascular, inflammatory, and neuroprotective pathways. AI-driven drug discovery has validated this approach, with Insilico Medicine reporting positive Phase IIa results for ISM001-055 targeting idiopathic pulmonary fibrosis through TNIK inhibition, while senolytics and epigenetic reprogramming therapies from companies like Rubedo Life Sciences, Unity Biotechnology, Life Biosciences, and Altos Labs have advanced into human clinical trials. The convergence of scientific validation, pharma investment exceeding $550 million in partnership deals, successful IPOs including BioAge Labs' $198 million offering, and regulatory progress on aging biomarkers has propelled longevity therapeutics from academic curiosity to a strategic priority for the global biopharma industry.ThelongevityinitiativeThe business of longevity in 2025: big bets amid biotech bustThe longevity biotech sector had a mixed 2025, with significant exits including Unity Biotechnology's September shutdown and AbbVie ending its collaboration with Calico Life Sciences, while notable successes included Eli Lilly's $1 billion acquisition of Verve Therapeutics for its PCSK9 gene editor and Insilico Medicine's approximately $293 million IPO on the Hong Kong Stock Exchange. AI-based drug discovery also showed strong momentum with Gero's over-$1 billion partnership with Chugai (Roche) and multiple Phase 3 trials ongoing targeting hallmarks of ageing.SkyquesttLongevity Anti-senescence Therapy Market Size, Share and AnalysisA market research report by SkyQuest Technology projects the global longevity anti-senescence therapy market will grow from USD 22.85 billion in 2024 to USD 72.58 billion by 2033, with a 13.7% CAGR, driven by an aging global population and advances in biotechnology including gene therapy and senolytic drug development. Key recent developments include Unity Biotechnology's positive Phase 2 trial results for diabetic macular oedema treatment and Rubedo Life Sciences securing $40 million in Series A funding for small-molecule therapies targeting aging cells. The report identifies North America as the largest market with the most sophisticated biotech ecosystem, while Asia-Pacific represents the fastest-growing region, with China and Japan emerging as significant innovation hubs for longevity research.Longevity.TechnologyInterviews of 2025: The innovatorsThe article discusses recent developments in longevity research, highlighting the closure of Unity Biotechnology after a trial failure but emphasizing its supportive data for senolytics; advancements in epigenetic rejuvenation with plans to enter human trials; the use of gene silencing to reverse cellular aging; a study showing benefits of plasma exchange on biological age; and the exploration of synthetic replacements for biological systems by Swiss startup Sciborg.